Penn Cancer Center Sponsors Exhibit of Cancer Patients’ Art

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 10
Volume 8
Issue 10

PHILADELPHIA-“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.

PHILADELPHIA—“Confronting Cancer Through Art” is a juried exhibition of inspirational artwork crafted by individuals who have been touched by cancer (see artwork). This year marks the second time that the University of Pennsylvania Cancer Center has sponsored this exhibit, which runs through October 31, 1999, at the Arthur Ross Gallery in Philadelphia. The first exhibit was presented in 1996.

 “Artmaking encourages vision, hope, and imagination, all of which foster the healing process,” said Gianna Volpe, MFA, who directs the Cancer Center’s Art Program and whose own artwork is part of the exhibit. The exhibit contains 65 pieces created in various media, including sculpture, quilting, painting, and photography. It can be viewed online until October 31, 1999, at the Center’s website: www.oncolink.upenn.edu.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
CAR T-cell therapy initially developed for mantle cell lymphoma was subsequently assessed in marginal zone lymphoma.
The efficacy of the BOVen regimen in chronic lymphocytic leukemia facilitated its evaluation in patients with mantle cell lymphoma.
2 experts in this video
2 experts in this video
Beta emitters like 177Lu-rosopatamab may offer built-in PSMA imaging during the treatment of patients with metastatic castration-resistant prostate cancer.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.